Get the Stockscreener App
0.345
9.69%
-0.037
After Hours:
.36
0.015
+4.35%
Xortx Therapeutics Inc stock is traded at $0.345, with a volume of 75,085.
It is down -9.69% in the last 24 hours and down -14.60% over the past month.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
See More
Previous Close:
$0.382
Open:
$0.41
24h Volume:
75,085
Relative Volume:
0.79
Market Cap:
$2.40M
Revenue:
-
Net Income/Loss:
$-2.66M
P/E Ratio:
-0.5749
EPS:
-0.6001
Net Cash Flow:
$-2.83M
1W Performance:
-15.85%
1M Performance:
-14.60%
6M Performance:
-56.88%
1Y Performance:
-63.68%
1-Day Range:
$0.345
$0.41
1-Week Range:
$0.345
$0.4321
52-Week Range:
$0.345
$1.41
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.345 | 2.66M | 0 | -2.66M | -2.83M | -0.6001 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
XORTX Announces Results of Annual and Special Meeting of Shareholders - GlobeNewswire Inc.
XORTX Announces Change of Effective Date of Share Consolidation - marketscreener.com
XORTX's 5-for-1 share consolidation is now scheduled for April 6 - Stock Titan
XORTX shareholders approve up-to-5-for-1 share consolidation to meet Nasdaq rules - MSN
Investment Recap: Is XORTX Therapeutics Inc in a long term uptrendMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
XORTX shrinks shares from 6.96M to 1.39M to stay on Nasdaq - Stock Titan
XORTX Therapeutics (XRTX) wins shareholder approval for up to 5-for-1 share consolidation - Stock Titan
XORTX needs its stock above $1. Shareholders approved a 5-for-1 consolidation - Stock Titan
If You Invested $1,000 in Xortx Therapeutics Inc (XRTX) - Stock Titan
Aug Highlights: Does XORTX Therapeutics Inc. have declining or rising EPS2026 Price Action Summary & Verified Chart Pattern Signals - baoquankhu1.vn
XRTX SEC FilingsXortx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
XRTX: Net loss improved to US$2.66M in 2025 as late-stage clinical programs advanced and cash reserves declined - TradingView
XORTX Therapeutics (NASDAQ: XRTX) outlines losses and drug pipeline - Stock Titan
XORTX Ties Board Shake-Up to Financing Ahead of March 24 Shareholder Vote - The Globe and Mail
Whale Trades: Can XORTX Therapeutics Inc continue delivering strong returnsEarnings Performance Report & Fast Gain Swing Trade Alerts - baoquankhu1.vn
XORTX Reshapes Board to Meet Conditions for Planned Financing - The Globe and Mail
Aug Macro: Does XORTX Therapeutics Inc have pricing power2026 Breakouts & Breakdowns & Stepwise Trade Signal Implementation - baoquankhu1.vn
Xortx Therapeutics announces three new director nominees - TipRanks
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders - markets.businessinsider.com
Street Watch: What is the cash position of XORTX Therapeutics Inc2026 Final Week & Trade Opportunity Analysis - baoquankhu1.vn
New XORTX (NASDAQ: XRTX) board nominees linked to key financing - Stock Titan
Pullback Watch: Is XORTX Therapeutics Inc a speculative investmentTrade Ideas & High Conviction Buy Zone Picks - baoquankhu1.vn
Proxy Advisers Back XORTX Share Consolidation Plan Ahead of March Vote - The Globe and Mail
ISS backs XORTX (NASDAQ: XRTX) share consolidation ahead March 2026 vote - Stock Titan
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation - Bitget
XORTX Brief: Reporting that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" Share Consolidation - marketscreener.com
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation - marketscreener.com
Whats the RSI of XORTX Therapeutics Inc stockMarket Growth Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
XORTX Therapeutics looks to raise $3M through private placement - MSN
XORTX Sets March 24 Shareholder Meeting, Seeks Approval for Share Consolidation and Governance Matters - The Globe and Mail
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders - Bitget
XORTX Therapeutics Completes Filing and Mailing of Documents for Annual and Special Shareholder Meeting - geneonline.com
XORTX seeks shareholder vote on up to 5-for-1 share consolidation - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
XORTX Calls March 24, 2026 Shareholder Meeting to Vote on Share Consolidation and Governance Matters - The Globe and Mail
XORTX (NASDAQ: XRTX) seeks share consolidation to meet $1 bid - Stock Titan
XORTX Files 2025 Annual Financials as Auditors Flag Going‑Concern Risk - The Globe and Mail
XRTX Should I Buy - Intellectia AI
XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
XORTX Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
XORTX Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
XRTXXortx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Sectors Review: Can XORTX Therapeutics Inc continue delivering strong returnsJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
What’s the beta of XORTX Therapeutics Inc. stockJuly 2025 Selloffs & Weekly High Return Opportunities - mfd.ru
Take Profit: What is the target price for XORTX Therapeutics Inc stock2025 Trade Ideas & Precise Trade Entry Recommendations - baoquankhu1.vn
XRTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can XORTX Therapeutics Inc. continue delivering strong returnsDay Trade & Reliable Price Action Trade Plans - mfd.ru
Is XORTX Therapeutics Inc. stock a buy before product launchesEarnings Performance Report & Smart Swing Trading Techniques - mfd.ru
Will XORTX Therapeutics Inc. outperform during market ralliesWeekly Stock Report & Growth Oriented Trade Recommendations - mfd.ru
Trading Action: What is XORTX Therapeutics Incs TAM Total Addressable MarketMarket Performance Recap & Verified Technical Signals - baoquankhu1.vn
XORTX Therapeutics Brief: Provided Overnight Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems - marketscreener.com
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):